Posts Tagged: biotechnology

MaRS Innovation: Ahead of Innovation video launched

To coincide with our presence at the 2016 BIO International Convention (BIO) from June 6-9, 2016, MaRS Innovation launched a video explaining our role in Canada's innovation ecosystem: backing big thinkers with bold ideas and working with them to take those breakthroughs to market. This year, BIO takes place in San Francisco, California, the birthplace of biotech. MaRS Innovation will be present in the Ontario Pavilion (Booth #5944) in partnership with the Ontario Government and Life Sciences Ontario. Both the Honourable Navdeep Bains, Canada's ... Read more

Accel-Rx and BDC Capital make second portfolio investment in ScarX Therapeutics

MaRS Innovation portfolio company completing Phase 1 human clinical trial of drug to prevent dermal scarring VANCOUVER (February 16, 2016) — Accel-Rx Health Sciences Accelerator (Accel-Rx), a Centre of Excellence for the Commercialization of Research (CECR), and its partner BDC Capital today announced their second joint investment in ScarX Therapeutics, a Canadian biotechnology company commercializing innovative treatments for dermal scarring (fibrosis). Accel-Rx and BDC Capital, and other investors including MaRS Innovation, have invested a total of $2 million in ScarX. This investment will ... Read more

Ontario Government Invests $1 Million in Toronto’s Neuroscience Catalyst Consortium

Ministry of Research & Innovation joins founding partners University of Toronto and Janssen Inc., and new partners Evotec AG, MaRS Innovation and Ontario Centres of Excellence, to advance treatments for neurological disorders and develop early-stage biotech companies TORONTO and PHILADELPHIA (June 16, 2015)— Toronto’s neuroscience efforts to find new drugs to treat and manage brain disorders — specifically, mood disorders and Alzheimer's disease — took another step forward as the Government of Ontario’s Ministry of Research and Innovation announced a $1 million ... Read more

Life Sciences Ontario’s statement on the 2015 Ontario Budget

TORONTO, ON (April 23, 2015) — Life Sciences Ontario (LSO) applauds the government's continued commitment to supporting life sciences through the Ontario Health Innovation Council and its accompanying $20 million innovation fund, programs to support job creation for Ontario’s highly educated young workforce and a new approach to providing the venture capital needed to support the commercialization of technologies and growth of companies in the life sciences sector. Specifically, LSO notes the following commitments from the 2015 budget that will help drive ... Read more

Encycle Therapeutics developing lead molecule to tackle inflammatory bowel disease

Company's collaborative partnership with IRICoR, Université de Montréal and MaRS Innovation, funded by Merck Canada, to advance macrocycle drug TORONTO and MONTREAL, Nov. 10, 2014 — Encycle Therapeutics Inc., a biotechnology start-up founded by Dr. Andrei Yudin of the University of Toronto in partnership with MaRS Innovation, is developing its lead orally-bioavailable macrocycle drug to target integrin a4b7, which is involved in the inflammatory process in a number of diseases, most notably for inflammatory bowel disease. This announcement was covered in SciBX, Drug Discovery ... Read more

BioCentury features Vasomune Therapeutics

Vasomune Therapeutics, a MaRS Innovation start-up company from Sunnybrook Health Sciences Centre's Sunnybrook Research Institute, was featured in a BioCentury emerging company profile by Michael J. Haas. The company is currently raising a Series A financing round and recently closed a seed investment with Genome Canada and an unnamed industry partner. MaRS Innovation also contributed a third of the investment, bringing the round's total to $1.5 million. Haas' profile, "Vasomune: Lassoing Tie2," is available behind a paywall on the BioCentury website. Here's a short ... Read more

MaRS Innovation joins new financing round for AvidBiologics Inc.

TORONTO, Sept. 29, 2014 — AvidBiologics Inc., an oncology drug development company, today announced the closing of a financing round. The company is founded on antibody-drug conjugate (ADC) technologies co-developed with the National Research Council of Canada (NRC). Led by Lumira Capital, the financing round included MaRS Innovation (MI), MaRS Investment Accelerator Fund (IAF), Rosseau Asset Management, and the company's founding investors. This announcement was covered by Dow Jones: Private Equity and Venture Capital and by Canadian Private Equity. Today's financing builds on prior ... Read more

Accel-Rx, the national health sciences accelerator, launches as a Centre of Excellence for Commercialization and Research (CECR)

MaRS Innovation among founding partner CECRs; Accel-Rx will provide funds to new biotechnology start-ups emerging within MI's portfolio VANCOUVER, BC (Aug. 25, 2014) –With the awarding of $14.5M under the Canadian government’s Networks of Centres of Excellence (Centres of Excellence for Commercialization and Research (CECR)) Program, as announced earlier this morning by the Honourable Ed Holder, Minister of State for Science and Technology, Accel-Rx - Canada’s Health Sciences Accelerator is officially launched. Media coverage of this announcement: CBC's Inside Politics blog, IT Business ... Read more

Dr. Rafi Hofstein in Biotechnology Focus: What will it take to regain Canada’s biotechnology leadership?

Biotechnology Focus, a compendium of the Canadian life sciences industry, has published a guest column by MaRS Innovation President & CEO, Dr. Raphael Hofstein. The article explores the role life sciences assets, financing and talented management--the three Ms--must play in revitalizing Canada's biotechnology sector: At the close of the 20th century, Canada was perceived as a key contributor to the success of the global biotech voyage. You know what happened next: the mechanisms to fund early ventures collapsed together with the collapse of the ... Read more

QSperm: Technology to help couples get pregnant faster

MaRS Innovation and U of T's Innovations & Partnerships Office collaborating with QSperm on intellectual property and business strategy In vitro fertility treatments can be intensely emotional and medically invasive, not to mention expensive. But technical developments from a research group at the University of Toronto may soon be able to shorten the journey to pregnancy – and that potential has piqued interest from international investors. The research group, QSperm, is looking to turn their research into a biotech start-up leveraging an innovative sperm sorting design ... Read more
Page 1 of 212